Gossamer Bio (NASDAQ:GOSS – Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.03), FiscalAI reports. The firm had revenue of $16.96 million during the quarter, compared to analyst estimates of $4.67 million.
Here are the key takeaways from Gossamer Bio’s conference call:
- Gossamer said its seralutinib Phase III PROSERA data showed a clinically meaningful improvement in six-minute walk distance, with all four key secondary endpoints favoring treatment, and management said the totality of the results supports a real treatment signal despite narrowly missing the prespecified alpha threshold.
- The company advanced its FDA pathway to a Type B pre-NDA meeting in mid-June and reiterated a target NDA filing in September 2026, with potential approval still viewed for the third quarter of 2027 if the process goes as planned.
- The PROSERA CT-FRI sub-study showed multi-compartment reverse remodeling, including improvements in arterial, venous, and fibrosis-like parenchymal measures, which management said provides mechanistic support for seralutinib’s effect in PAH.
- Management said the imaging findings are not a surrogate endpoint but could strengthen the NDA and potentially support a differentiated label, with the data expected to be included in the filing and discussed further with FDA.
- Gossamer also disclosed aggressive cost actions, including a reduction in force affecting about half the company, reduced operating expenses, and a convertible note exchange that lowers debt from $200 million to $72 million while extending maturity to 2030.
Gossamer Bio Price Performance
Gossamer Bio stock opened at $0.20 on Wednesday. Gossamer Bio has a 1-year low of $0.16 and a 1-year high of $3.87. The stock has a market cap of $46.73 million, a PE ratio of -0.25 and a beta of 2.15. The stock’s fifty day moving average is $0.38 and its two-hundred day moving average is $1.80.
Key Stories Impacting Gossamer Bio
- Negative Sentiment: Multiple law firms issued class-action alerts and deadline reminders for Gossamer Bio investors, highlighting lawsuits tied to alleged disclosures around trial risks and the February 23 PROSERA setback. Article Title
- Negative Sentiment: The securities class action centers on Gossamer’s Phase 3 PROSERA study failing to meet its primary endpoint, which is the core event behind the stock’s recent weakness. Article Title
- Negative Sentiment: The company also disclosed first-quarter 2026 results that missed earnings expectations, reinforcing concerns about profitability and execution. Article Title
- Neutral Sentiment: Gossamer Bio announced an exchange offer and consent solicitation aimed at eliminating more than $120 million of debt, which could improve its balance sheet if completed successfully. Article Title
- Neutral Sentiment: The company also said it is targeting a September 2026 NDA filing for seralutinib, with potential approval in Q3 2027, keeping the pipeline story alive but still years from commercialization. Article Title
Institutional Trading of Gossamer Bio
A number of hedge funds and other institutional investors have recently bought and sold shares of GOSS. Bank of America Corp DE raised its stake in Gossamer Bio by 107.2% in the fourth quarter. Bank of America Corp DE now owns 84,788 shares of the company’s stock valued at $77,000 after buying an additional 43,866 shares in the last quarter. Invesco Ltd. acquired a new stake in shares of Gossamer Bio during the first quarter worth about $48,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Gossamer Bio during the first quarter worth about $213,000. Goldman Sachs Group Inc. increased its position in shares of Gossamer Bio by 720.2% during the first quarter. Goldman Sachs Group Inc. now owns 939,603 shares of the company’s stock worth $1,034,000 after purchasing an additional 825,047 shares in the last quarter. Finally, Jane Street Group LLC increased its position in shares of Gossamer Bio by 5,250.1% during the first quarter. Jane Street Group LLC now owns 683,423 shares of the company’s stock worth $752,000 after purchasing an additional 670,649 shares in the last quarter. 81.23% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several research analysts have recently commented on the company. Cantor Fitzgerald restated a “neutral” rating on shares of Gossamer Bio in a research report on Monday, March 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of Gossamer Bio in a research report on Tuesday, April 21st. Oppenheimer lowered their price target on Gossamer Bio from $12.00 to $3.00 and set an “outperform” rating for the company in a research report on Thursday, March 5th. HC Wainwright reduced their price objective on Gossamer Bio from $10.00 to $5.00 and set a “buy” rating on the stock in a research note on Friday, March 6th. Finally, Wedbush reiterated a “neutral” rating and issued a $1.00 price objective (down from $6.00) on shares of Gossamer Bio in a research note on Tuesday, February 24th. Four analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $5.00.
Read Our Latest Research Report on Gossamer Bio
Gossamer Bio Company Profile
Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.
The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.
Featured Stories
- Five stocks we like better than Gossamer Bio
- Block’s Pivot to Profits and AI Is Turning Heads
- HIVE Weaponizes Power for an AI Pivot
- A Deep Dive Into NVIDIA’s Latest Portfolio Moves
- Brady Corp Wires Up a Massive AI-Powered Breakout
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.
